Plaque Psoriasis

Andrea Nguyen, MS, PA-C, reviews commonly used therapies for the initial treatment of plaque psoriasis.

Neal Bhatia, MD, provides an overview of the spectrum of disease, topical choices, and transitioning to oral medications for the treatment of plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss the current role of topical therapy and the use of non-biologic oral systemic and standard therapies for plaque psoriasis treatment.

An expert nurse practitioner and a physician assistant examine the role of collaborative care in the management of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, highlight the importance of the initial patient/provider conversation in guiding treatment of plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, discusses the various challenges care providers face when selecting treatment for patients with plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, shares his approach to building trust in the patient-provider relationship when counseling patients about treatment of plaque psoriasis.

Matthew T. Reynolds, PA-C, shares his treatment approach to plaque psoriasis based on the expanding therapeutic landscape.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, provide an overview of the pathogenesis of plaque psoriasis and how our understanding of the condition has evolved.

Neal Bhatia, MD, FAAD, reviews the clinical implications of roflumilast, a newly approved topical agent for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, provides an overview of the efficacy and safety results of the DERMIS 1 and DERMIS 2 trials for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, discusses the current treatment landscape for patients with chronic plaque psoriasis, focusing specifically on PDE4 inhibitors.

Dermatology experts discuss the rapid expansion of the treatment armamentarium of plaque psoriasis and how has it shifted treatment approaches to plaque psoriasis.

Brad Glick, DO, AOCD, leads a discussion about the current therapeutic landscape and approval of various biologics therapies for the management plaque psoriasis.

This newly-approved monoclonal antibody was developed as a citrate-free formulation of adalimumab.

New research into bimekizumab for psoriatic arthritis suggests the treatment to be effective for joint and skin improvements at 16 weeks.

Darren West, MPAS, PA-C, and Douglas DiRuggiero, DMSc, PA-C, talk about how the treatment of plaque psoriasis has changed as understanding of the disease grows.

Experts in dermatology discuss how clinician understanding of plaque psoriasis has evolved over time.

This year saw 4 new FDA approvals for the chronic condition. But dermatologists are still not satisfied.

Leon Kircik, MD, shares his impressions of the long-term data of roflumilast, and where it fits into clinical practice.

Leon Kircik, MD, reviews a recent study of roflumilast and its long-term efficacy and safety data in chronic plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, comments on the need for multidisciplinary care providers in light of comorbidities in plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, reviews the role of nurse practitioners, physician assistants, and pharmacists in managing plaque psoriasis.

New research highlights the growing number of claims among all providers, including advanced practice practitioners and non-dermatologists, of Cal/BD foam usage for Medicare beneficiaries.

A discussion with Emily Strouphauer on her team's findings regarding mental health in pediatric psoriasis, as well as her views on helping younger patients facing these issues.